Готові списки джерел за темами / Early ischaemic heart disease

Добірка наукової літератури з теми "Early ischaemic heart disease"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Early ischaemic heart disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Early ischaemic heart disease"

1

Penna, Claudia, Saveria Femminò, Giuseppe Alloatti, Maria F. Brizzi, Tommaso Angelone, and Pasquale Pagliaro. "Extracellular Vesicles in Comorbidities Associated with Ischaemic Heart Disease: Focus on Sex, an Overlooked Factor." Journal of Clinical Medicine 10, no. 2 (January 17, 2021): 327. http://dx.doi.org/10.3390/jcm10020327.

Повний текст джерела
Анотація:
Extracellular vesicles (EV) are emerging early markers of myocardial damage and key mediators of cardioprotection. Therefore, EV are becoming fascinating tools to prevent cardiovascular disease and feasible weapons to limit ischaemia/reperfusion injury. It is well known that metabolic syndrome negatively affects vascular and endothelial function, thus creating predisposition to ischemic diseases. Additionally, sex is known to significantly impact myocardial injury and cardioprotection. Therefore, actions able to reduce risk factors related to comorbidities in ischaemic diseases are required to prevent maladaptive ventricular remodelling, preserve cardiac function, and prevent the onset of heart failure. This implies that early diagnosis and personalised medicine, also related to sex differences, are mandatory for primary or secondary prevention. Here, we report the contribution of EV as biomarkers and/or therapeutic tools in comorbidities predisposing to cardiac ischaemic disease. Whenever possible, attention is dedicated to data linking EV to sex differences.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Rasmiena, Aliki A., Theodore W. Ng, and Peter J. Meikle. "Metabolomics and ischaemic heart disease." Clinical Science 124, no. 5 (November 12, 2012): 289–306. http://dx.doi.org/10.1042/cs20120268.

Повний текст джерела
Анотація:
Ischaemic heart disease accounts for nearly half of the global cardiovascular disease burden. Aetiologies relating to heart disease are complex, but dyslipidaemia, oxidative stress and inflammation are cardinal features. Despite preventative measures and advancements in treatment regimens with lipid-lowering agents, the high prevalence of heart disease and the residual risk of recurrent events continue to be a significant burden to the health sector and to the affected individuals and their families. The development of improved risk models for the early detection and prevention of cardiovascular events in addition to new therapeutic strategies to address this residual risk are required if we are to continue to make inroads into this most prevalent of diseases. Metabolomics and lipidomics are modern disciplines that characterize the metabolite and lipid complement respectively, of a given system. Their application to ischaemic heart disease has demonstrated utilities in population profiling, identification of multivariate biomarkers and in monitoring of therapeutic response, as well as in basic mechanistic studies. Although advances in magnetic resonance and mass spectrometry technologies have given rise to the fields of metabolomics and lipidomics, the plethora of data generated presents challenges requiring specific statistical and bioinformatics applications, together with appropriate study designs. Nonetheless, the predictive and re-classification capacity of individuals with various degrees of risk by the plasma lipidome has recently been demonstrated. In the present review, we summarize evidence derived exclusively by metabolomic and lipidomic studies in the context of ischaemic heart disease. We consider the potential role of plasma lipid profiling in assessing heart disease risk and therapeutic responses, and explore the potential mechanisms. Finally, we highlight where metabolomic studies together with complementary -omic disciplines may make further inroads into the understanding, detection and treatment of ischaemic heart disease.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

MORALIDIS, E. "betaBlockers enhance early diastolic filling in ischaemic heart disease: a radionuclide assessment." Heart 86, no. 4 (October 1, 2001): 457. http://dx.doi.org/10.1136/heart.86.4.457.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ryan, Matthew, Holly Morgan, Mark C. Petrie, and Divaka Perera. "Coronary revascularisation in patients with ischaemic cardiomyopathy." Heart 107, no. 8 (January 12, 2021): 612–18. http://dx.doi.org/10.1136/heartjnl-2020-316856.

Повний текст джерела
Анотація:
Heart failure resulting from ischaemic heart disease is associated with a poor prognosis despite optimal medical treatment. Despite this, patients with ischaemic cardiomyopathy have been largely excluded from randomised trials of revascularisation in stable coronary artery disease. Revascularisation has multiple potential mechanisms of benefit, including the reversal of myocardial hibernation, suppression of ventricular arrhythmias and prevention of spontaneous myocardial infarction. Coronary artery bypass grafting is considered the first-line mode of revascularisation in these patients; however, evidence from the Surgical Treatment of Ischaemic Heart Failure (STICH) trial showed a reduction in mortality, though this only became apparent with extended follow-up due to an excess of early adverse events in the surgical arm. There is currently no randomised controlled trial evidence for percutaneous coronary intervention in patients with ischaemic cardiomyopathy; however, the REVIVED-BCIS2 trial has recently completed recruitment and will address this gap in the evidence. Future directions include (1) clinical trials of revascularisation in patients hospitalised with heart failure, (2) defining the role of viability and ischaemia testing in heart failure, (3) studies to enhance the understanding of the mechanistic effects of revascularisation and (4) generating models to refine pre- and post-revascularisation risk prediction.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

SECKL, J. "Early life events and later development of Ischaemic heart disease." Lancet 342, no. 8881 (November 1993): 1236. http://dx.doi.org/10.1016/0140-6736(93)92215-f.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Rahman, Md Mahbubu, Md Aminur Razzaque, Iftikher Alam, Asif Iqbal, Golam Rahman Mallick, Swati Munshi, Md Wareshuzzaman, and AK Mohammad Qudrath E. Hasan. "Cardiac Cephalgia: Angina in the Head." Bangladesh Medical Journal 48, no. 3 (February 2, 2021): 46–49. http://dx.doi.org/10.3329/bmj.v48i3.51798.

Повний текст джерела
Анотація:
Cardiac cephalgia is a migraine like headache that occurs during episodes of myocardial ischaemia. Although most of the patients presenting with ischaemic heart disease have chest pain, there are other rare presenting symptoms like cardiac cephalgia. Headache can be the only presentation of coronary artery disease. We report a case of a 57 years-old man, Presenting with only headache during brisk walking, Exercise Tolerance Test (ETT) was positive for Electrocardiograph (ECG) evidence of provocable myocardial ischemia, who latter was diagnosed as double vessel coronary artery diseaseon Coronary Angiogram (CAG). As the patient preferred remaining without revascularization, he was put onto optimum medical management for ischaemic heart disease. A follow up visit after one month revealed, marked improvement of the headache with anti anginal medications. Early evaluation and diagnosis of the headache symptom should be done because treatment with anti-migraine drugs may deteriorate headache and undermine the diagnosis of coronary artery disease. Bangladesh Med J. 2019 Sep; 48 (3): 46-49
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Søndergaard, Grethe, Susanne Oksbjerg Dalton, Laust Hvas Mortensen, and Merete Osler. "Educational inequality in cardiovascular diseases: a sibling approach." Scandinavian Journal of Public Health 46, no. 1 (October 9, 2017): 83–91. http://dx.doi.org/10.1177/1403494817734775.

Повний текст джерела
Анотація:
Aims: Educational inequality in diseases in the circulatory system (here termed cardiovascular disease) is well documented but may be confounded by early life factors. The aim of this observational study was to examine whether the associations between education and all cardiovascular diseases, ischaemic heart disease and stroke, respectively, were explained by family factors shared by siblings. Methods: The study population included all individuals born in Denmark between 1950 and 1979 who had at least one full sibling born in the same period. Using Cox regression, data were analysed in conventional cohort and within-sibship analyses in which the association was examined within siblings discordant on education. Assuming that attenuation of associations in the within-sibship as compared with the cohort analyses would indicate confounding from factors shared within families. Results: A lower educational status was associated with a higher risk of cardiovascular disease, ischaemic heart disease and stroke. All associations attenuated in the within-sibship analyses, in particular in the analyses on ischaemic heart disease before age 45 years. For instance, in the cohort analyses, the hazard rate of ischaemic heart disease among women less than 45 years who had a primary school education was 94% (hazard ratio 1.94 (1.78–2.12) higher than among those with a vocational education, while it attenuated to 51% (hazard ratio 1.51 (1.34–1.71)) in the within-sibship analysis. Conclusions: Confounding from factors shared by siblings explained the associations between education and the cardiovascular disease outcomes but to varying degrees. This should be taken into account when planning interventions aimed at reducing educational inequalities in the development of cardiovascular disease, ischaemic heart disease and stroke.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Muradov, A. G., V. U. Efendiev, A. V. Andin, D. B. Drobot, D. P. Demidov, and V. A. Sakovich. "The history of coronary surgery development." Siberian Medical Review, no. 3 (2021): 15–25. http://dx.doi.org/10.20333/25000136-2021-3-15-25.

Повний текст джерела
Анотація:
The leading place among cardiovascular diseases in the world – 50% – belongs to the ischaemic heart disease. Coronary bypass grafting is the golden standard for treatment of patients with multivessel ischaemic heart disease. The modern level of coronary surgery makes it possible to perform safe and efficacious direct revascularisation with hospital lethality not exceeding 1-3%. This article presents a review of literature devoted to the history of coronary surgery development including analysis of relevant sources dated 2010-2020 published in PubMed and Google Scholar databases: from first experimental procedures in the beginning of the 20th century and indirect myocardial revascularisation methods to direct bypass grafting of the impaired heart vessels actively developed since early 1960s. The article describes types of grafts applied with description of advantages and disadvantages of each one as well as contemporary methods and conditions for coronary bypass grafting and further prospects in development of ischaemic heart disease surgery.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Dorofeeva, N. P., S. A. Pleskachev, S. V. Shlyk, E. V. Tchigaeva, E. A. TherAnanyanz, O. G. Mashtalova, I. E. Koulikova, A. S. Pleskachev, and S. S. Todorov. "CLINICAL AND PATHOGENETIC ASPECTS OF ISCHAEMIC HEART DISEASE COMPLICATED BY CHTONIC HEART FAILURE." Journal of Clinical Practice 2, no. 1 (March 15, 2011): 67–73. http://dx.doi.org/10.17816/clinpract2167-73.

Повний текст джерела
Анотація:
Objectives: To investigate genetic and neurohumoral determinants of chronic heart failure (CHF) development and progression in ischaemic heart disease (IHD) patients. Methods: Serum neurohormone level analysis (angiotensin II, aldosterone, endotheline1, NTproBNP, TNFα) and genotyping (genes encoding ACE, angiotensinogen, and type1 angiotensin II receptors ) were implemented in 100 patients Results: Activation of endotheline and NTproBNP is characteristic of early CHF stages while decompensation of chronic heart failure shows elevation in aldosterone and TNFα . Structural polymorphism of renineangiotensine system genes is not significant in CHF development and progression in IHD patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Evans-Cheung, Trina C., H. Jonathan Bodansky, Roger C. Parslow, and Richard G. Feltbower. "Early deaths from ischaemic heart disease in childhood-onset type 1 diabetes." Archives of Disease in Childhood 103, no. 10 (January 24, 2018): 981–83. http://dx.doi.org/10.1136/archdischild-2017-314265.

Повний текст джерела
Анотація:
AimsThe risk of ischaemic heart disease (IHD) death in early type 1 diabetes onset was assessed using death certification data.MethodsThe Yorkshire Register of type 1 Diabetes in Children and Young People was linked to clinically validated death certification data for those diagnosed under 15 years. Standardised mortality ratios (SMRs) were calculated using the England and Wales population and IHD death rates between 1978 and 2014 by 5-year age group and sex.ResultsThe cohort included 4382 individuals (83 097 person years). Of 156 deaths, nine were classed as IHD deaths before clinical validation. After clinical validation, 14 IHD deaths were classified, with an SMR of 13.8 (95% CI 8.2 to 23.3) and median age at death of 35.1 years (range 21.9–47.9 years).ConclusionsThere is an early emergence of death from IHD in early onset type 1 diabetes. Underascertainment of IHD deaths was present without clinical validation of death certification.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Early ischaemic heart disease"

1

Hamshere, Stephen. "Investigation of the effect of early intracoronary autologous bone marrow cell infusion in the management and treatment of acute myocardial infarction." Thesis, Queen Mary, University of London, 2017. http://qmro.qmul.ac.uk/xmlui/handle/123456789/30705.

Повний текст джерела
Анотація:
Cardiovascular disease (CVD) is a complex combination of multiple conditions. The majority of deaths within CVD include heart attacks and strokes caused by atherosclerotic disease. The pathophysiological process for atherosclerotic disease occurs within the endothelial lining of the vessels of the body. This prolonged process occurs when cholesterol deposits form irregularity in luminal flow resulting in decreased blood flow and ischaemia. This unstable cholesterol plaque can rupture resulting in clot formation and artery occlusion. Within this thesis I aim to show background to the relevant pathophysiology of ischaemic heart disease (IHD) with the main emphasis on acute myocardial infarction (AMI), the history of its therapy to current therapy. I will discuss the theorised role of stem cell therapy within animal models and previous clinical trials within regenerative medicine and AMI. I will describe and discuss the method and the results of the REGENERATE-AMI trial (Clintrial.gov: NCT00765453), which will include the safety and efficiency of the therapy, and the possible cytokine mechanism by which this therapy may exert it effect. Additionally I will describe the potential for assessing myocardial oedema using 3-slice T2-STIR short axis stack imaging post AMI compared to the conventional 10-slice T2-STIR technique to assess its feasibility and clinical similarity to assess its use as a tool in translational research.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Wikström, Anna-Karin. "Biochemical and Epidemiological Studies of Early-Onset and Late-Onset Pre-Eclampsia." Doctoral thesis, Uppsala University, Department of Women's and Children's Health, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8279.

Повний текст джерела
Анотація:

Biochemical and epidemiological aspects of pre-eclampsia were investigated, with the main focus on possible pathophysiological differences between early-onset and late-onset disease.

In pre-eclamptic women poor correlation was found between albumin-creatinine ratio (ACR) in a random urine sample and total amount of albumin in a 24-hour urine collection. (Paper I)

In a cohort of women giving birth in Sweden in 1973-82 we estimated the adjusted incidence rate ratio (IRR) for ischaemic heart disease (IHD) during the years 1987–2001. The adjusted IRR for development of IHD was 1.6-2.8 in woman exposed to gestational hypertensive disease during her pregnancy compared with unexposed women. The higher risk represents more severe or recurrent hypertensive disease. (Paper II)

Before delivery, in early-onset pre-eclampsia (24-32 weeks) there were pronounced alterations in plasma concentrations of soluble fms-like tyrosine kinase 1 (sFlt1) and placental growth factor (PlGF), and also a higher placental 8-iso-PGF2α concentration and an elevated serum ratio of plasminogen-activator inhibitor (PAI)-1 to PAI-2 compared with early controls. In late-onset pre-eclampsia (35-42 weeks) there were only moderate alterations in sFlt1 and PlGF concentrations, and the placental 8-iso-PGF2α concentration and PAI-1/ PAI-2 ratio were similar to those in late controls. (Papers III, V) There was a rapid postpartum decrease in sFlt1 concentration in all groups. One week postpartum the sFlt1 concentration was persistently higher, however, in women with early-onset pre-eclampsia compared with early controls. (Paper IV)

In conclusion: random ACR cannot replace 24-hour urine collections for quantification of albuminuria in pre-eclamptic women; gestational hypertensive disease, especially severe or recurrent, increases the risk for later IHD; early-onset, but not late-onset pre-eclampsia is associated with pronounced alterations of angiogenesis-related markers and only early-onset pre-eclampsia is associated with placental oxidative stress and an increased PAI-1/ PAI-2 ratio, all suggesting a stronger link between early-onset than late-onset pre-eclampsia and a dysfunctional placenta.

Стилі APA, Harvard, Vancouver, ISO та ін.
3

O'Sullivan, Christine Ann. "Electromechanical changes in ischaemic heart disease." Thesis, Imperial College London, 2006. http://hdl.handle.net/10044/1/8251.

Повний текст джерела
Анотація:
In coronary artery disease,. resting electrical and mechanical function of the left ventricle may vary according to different presentations. Stress or exercise in these patients results in electrical disturbances, which may havc mechanical consequences. The objectives ofthis thesis were: I) to assess the effect of the presence and location of Q wave myocardial infarction on left ventricular segmental mechanical function and identify patterns ofdisturbances. 2) to study the acute implications of induction of localised myocardial infarction at the proximal ventricular septum on ventricular performance. 3) to determine the effect of pharmacological stress on left and right ventricular behaviour in patients with coronary artery disease. AIl patients were studied by Doppler echocardiography using conventional measurements, as well as detailed assessment of long axis function and 12 lead surface EeG's. The foHowing groups ofpatients were studied: a). 72 patients with old Q wave MI; 35 anterior and 37 inferior. b) 54 patients with old anterior MI; 39 Q wave and 15 non-Q wave MI. c) 20 symptomatic patients with hypertrophic obstructive cardiomyopathy before and after non-surgical septal reduction therapy. d) . 27 patients with coronary artery disease, at rest and during dobutamine stress to assess left ventricular fune:tion. e) 33 patients with triple coronary artery disease at rest and at peak dobutamine stress to assess right ventricular function. The normal septal Q wave was' absent in 94% of anterior and 8% of inferior MI patients. Long axis amplitude and shortening and lengthening velocities were globaIly reduced in anterior and inferior myocardial infarction and the onset of shortening and lengthening were delayed by 30-40ms and 20-30 ms respectively in the two patient groups. Post ejection ~hortening was localised to the septum in the majority of patients with anterior myocardial infarction, but was generalised in patients with inferior infarction. 1) The normal septal Q wave was absent in 10% of control subjects and in 46% of patients with non-Q wave myocardial infarction. Q wave anterior MI was associated with a scarred septum and dilated LV cavity. Long axis amplitude was not different from normal in non-Q wave-infarction, but its onset ofshortening and lengthening was delayed by 20ms. Post ejection shortening occurred more frequently in Q wave infarction (76%) compared with non-Q wave infarction (21 %). These .abnormalities were localised to the left rand septal sites in non-Q wave infarction in contrast to their global distribution in Q wave infarction. . 2) Induction of localised upper septal myocardial infarction with alcohol resulted in broadening of the QRS (by 35ms), RBBB in 80% of patients, development of reduced septal long axis amplitude, and accentuated post ejection shortening at the septal long axis site. 3) In contrast to controls, dobutamine stress results in progressive broadening of QRS duration and prolongation of the QTc interval in patients with coronary artery disease, with corresponding reductions in long axis amplitude of motion and peak lengthening .velocity. 4) In patients with triple vessel coronary disease, dobutamine stress results in right ventricular long axis ischaemic disturbances similar to those seen on the left. Failure ofright ventricular long axis amplitude to increase by 2 mm was 88% specific for detecting right ventricular ischaemic dysfunction, which also correlated with the attenuated cardiac output at peak stress r= 0.56, p
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Horan, P. G. "Unravelling the genetic basis of ischaemic heart disease." Thesis, Queen's University Belfast, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.426746.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Byrne, Conor James. "Ischaemic and pharmacological preconditioning of the uraemic heart." Thesis, Queen Mary, University of London, 2011. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8831.

Повний текст джерела
Анотація:
The incidence and mortality from cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) far exceeds that seen in the general population. Whilst a number of risk factors and associations have been identified in patients with CKD that may contribute to the increased risk of CVD, our understanding of the underlying pathophysiology remains poor. It has previously been reported that uraemic animals sustain larger myocardial infarcts and that this ‘reduced ischaemia tolerance’ may in part explain the excess mortality from CVD seen in CKD patients. The aim of this work was to establish an in vivo model of uraemic myocardial infarction in order to further explore the pathophysiology of uraemic CVD with particular focus on ameliorating myocardial ischaemia-reperfusion injury using ischaemic and pharmacological preconditioning. An increase in myocardial infarct size was demonstrated in the sub-total nephrectomy model of chronic uraemia, confirming previous reports in the literature. However, infarct size was not found to be increased in adenine diet induced renal failure. In addition, it was demonstrated for the first time, that the techniques of ischaemic preconditioning (IPC) and remote ischaemic preconditioning (RIPC) are both efficacious and not attenuated by chronic uraemia induced by sub-total nephrectomy or adenine diet (IPC only). Investigations were undertaken using an agent (a HIF stabiliser, FG4497) to induce pharmacological preconditioning in both animals with renal insufficiency and those without. These studies demonstrate that stabilisation of hypoxia inducible factor (HIF) may be a promising strategy to induce pharmacological preconditioning. It is hoped that this work may lay the foundations for future investigations to determine why sub-totally nephrectomised rats have larger infarcts whilst those with adenine induced renal failure, with a substantially greater degree of renal dysfunction, do not. Moreover, it is hoped that; by demonstrating that uraemia 3 does not prevent or attenuate the myocardial protection afforded by ischaemic preconditioning, the recruitment of patients with CKD will be encouraged to clinical trials of both ischaemic preconditioning and other therapies to limit myocardial infarction.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Awad, Wael Ibrahim Issa. "Ischaemic preconditioning in the neonatal rat heart." Thesis, King's College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.391636.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

O'Kane, Peter Danny. "The role of nitric oxide in ischaemic heart disease." Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.420333.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Mackie, Eileen Elizabeth. "Exercise and haemostasis in health and ischaemic heart disease." Thesis, University of Glasgow, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433574.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Claesson, Maria. "Women's hearts : ischaemic heart disease and stress management in women." Doctoral thesis, Umeå : Department of Public Health and Clinical Medicine, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-725.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Teece, Stewart. "The assessment of ischaemic heart disease in the emergency department." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.499952.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Early ischaemic heart disease"

1

Perrins, E. J. Ischaemic heart disease. Guildford: Update - Siebert, 1987.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Bray, Colin. Ischaemic heart disease. London: Update, 1986.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Rankin, A. C. Ischaemic heart disease. Guildford: Update-Siebert, 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

M, Fox Kim, ed. Ischaemic heart disease. Lancaster, England: MTP Press, 1987.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Fox, Kim M., ed. Ischaemic Heart Disease. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3211-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Meade, T. W. Haemostatic variables, thrombosis and ischaemic heart disease. Amsterdam: Excerpta Medica, 1995.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Gunnell, David. The invasive management of ischaemic heart disease. Bristol: Health Care Evaluation Unit, University of Bristol, 1994.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

de Luna, A. Bays, and M. Fiol-Sala, eds. The Surface Electrocardiography in Ischaemic Heart Disease. Oxford, UK: Blackwell Publishing, 2007. http://dx.doi.org/10.1002/9780470696248.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Edwards, Eric William. Population variation for risk variables in ischaemic heart disease. Oxford: OxfordPolytechnic, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Porter, Marilyn. Human plasma glutathione peroxidase as a risk factor for ischaemic heart disease. Manchester: University of Manchester, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Early ischaemic heart disease"

1

Aronow, Wilbert S. "Ischaemic Heart Disease." In Cardiovascular Disease and Health in the Older Patient, 152–71. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781118451786.ch7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Fry, John, Gerald Sandler, and David Brooks. "Ischaemic Heart Disease." In Disease Data Book, 20–48. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4149-6_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Collison, Damien, and Keith G. Oldroyd. "Ischaemic Heart Disease." In Textbook of Vascular Medicine, 355–63. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16481-2_33.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Aronow, Wilbert S. "Ischaemic Heart Disease." In Pathy's Principles and Practice of Geriatric Medicine, 437–47. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781119952930.ch37.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Ross, Donald N., Terence A. H. English, and Roxane McKay. "Ischaemic Heart Disease." In Principles of Cardiac Diagnosis and Treatment, 231–43. London: Springer London, 1992. http://dx.doi.org/10.1007/978-1-4471-1470-3_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Fry, John. "Ischaemic Heart Disease." In Common Diseases, 151–60. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-4924-9_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Michaud, Katarzyna. "Ischaemic Heart Disease." In Cardiac Pathology, 137–51. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24560-3_7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Marmot, M. G., and J. I. Mann. "Epidemiology of ischaemic heart disease." In Ischaemic Heart Disease, 1–31. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3211-1_1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Davies, M. J. "Pathology of ischaemic heart disease." In Ischaemic Heart Disease, 33–68. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3211-1_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hoffman, J. I. E. "Coronary physiology and pathophysiology." In Ischaemic Heart Disease, 69–89. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3211-1_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Early ischaemic heart disease"

1

Petrova, M., S. Prokopenko, O. Eryomina, E. Mozheyko, D. Kaskaeva, and O. Gavrilyuk. "COGNITIVE PROBLEMS IN PATIENTS WITH ISCHAEMIC HEART DISEASE IN THE EARLY POSTOPERATIVE PERIOD AFTER CORONARY ARTERY BYPASS GRAFTING." In PSYCHOLOGICAL HEALTH OF THE PERSON: LIFE RESOURCE AND LIFE POTENTIAL. Verso, 2017. http://dx.doi.org/10.20333/2541-9315-2017-416-424.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Haxhibeqiri-Karabdić, Ilirijana, Emir Kabil, and Haris Vranić. "ISCHAEMIC HEART DISEASE – SURGICAL TREATMENT AND POST-OPERATIVE COMPLICATIONS." In Acquired Heart Diseases. Academy of Sciences and Arts of Bosnia and Herzegovina, 2015. http://dx.doi.org/10.5644/pi2015-158-07.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Xing, Ruiming, and James Meng. "Machine Learning for Ischaemic Heart Disease Diagnostic Analysis." In 2022 IEEE 4th Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability (ECBIOS). IEEE, 2022. http://dx.doi.org/10.1109/ecbios54627.2022.9944997.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Patel, Anant R. C., Gavin C. Donaldson, Alexander J. Mackay, Jadwiga A. Wedzicha, and John R. Hurst. "Health Status In Patients With Chronic Obstructive Pulmonary Disease And Comorbid Ischaemic Heart Disease." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2614.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Marshall, Adele H., Laura A. Hill, and Frank Kee. "Continuous Dynamic Bayesian networks for predicting survival of ischaemic heart disease patients." In 2010 IEEE 23rd International Symposium on Computer-Based Medical Systems (CBMS). IEEE, 2010. http://dx.doi.org/10.1109/cbms.2010.6042637.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kuang, Silin, and See Meng Khoo. "Obstructive sleep apnoea and nocturnal arrhythmias in patients with ischaemic heart disease." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4178.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Ashraf, Saadia, and Amber Ashraf. "Study Of Risk Factors For Arrhythmias Among Chronic Obstructive Pulmonary Disease Patients Having Ischaemic Heart Disease." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2461.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Katz, D., S. Tiosano, D. Comaneshter, A. D. Cohen, and H. Amital. "SAT0690 The association between sarcoidosis and ischaemic heart disease – a big data analysis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6887.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Banks, MJ, EJ Flint, PA Bacon, and GD Kitas. "OP0013 Prevalence, clinical expression and causes of ischaemic heart disease in rheumatoid arthritis." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.1022.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Larsen, Ann Dyreborg, Harald Hannerz, Karen Albertsen, Hermann Burr, Martin Lindhardt Nielsen, Jan Hyld Pejtersen, and Anne Helene Garde. "1252 Long weekly working hours and risk of ischaemic heart disease and stroke." In 32nd Triennial Congress of the International Commission on Occupational Health (ICOH), Dublin, Ireland, 29th April to 4th May 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/oemed-2018-icohabstracts.1367.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Early ischaemic heart disease"

1

Zhou, Zhuo, Guixing Xu, Liuyang Huang, Hao Tian, Fengyuan Huang, Yilin Liu, Mingsheng Sun, and Fanrong Liang. Effectiveness and Safety of Electroacupuncture for Depression: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0068.

Повний текст джерела
Анотація:
Review question / Objective: Is electroacupuncture a safe therapy for the treatment of depression? Is electroacupuncture effective for the treatment of depression, as compared with sham control, or conventional drugs？ Condition being studied: Depression is a mood disorder that causes sufferers to feel sadness, decreased interest, guilt, self-blame, loss of energy, and experience sleep disorders such as insomnia. People suffering from depression even feel they have no way out and have suicidal thoughts. In the United States, the prevalence of a major depressive disorder is 16.2%1-3. The 2010 Global Burden of Disease Study identified major depression as the second leading cause of disability worldwide and a leading cause of the burden of suicide and ischaemic heart disease. At present, depression patients are mainly treated with antidepressants, but the efficacy is extremely unstable. Studies have shown that acupuncture can help improve symptoms in patients with depression, but these clinical studies have not been systematically evaluated, and further confirmation is needed to confirm the efficacy of electroacupuncture in treating depression.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Corticosteroids given early reduce risk of heart problems in children with Kawasaki disease. National Institute for Health Research, February 2017. http://dx.doi.org/10.3310/signal-000380.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Early ischaemic heart disease" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії